GreenVax Selects Xcellerex Single-Use Bioreactor

Project GreenVax has agreed to acquire XDR GMP single-use production bioreactors from Xcellerex. The systems will be deployed in a new facility currently under construction in Bryan, TX. Project GreenVax is spearheaded by Texas Plant-Expressed Vaccine Consortium, which consists of G-Con, LLC and The Texas A&M University System. Financial terms were not disclosed.

“The XDR system has been demonstrated to be very adaptable and effective in growing wide variety of organisms to support our process needs,” commented Dr. Barry Holtz, president of G-Con. “The XDR system was selected for several reasons, including competitive capital costs, and a lower overall operating cost compared to that of conventional steam-in-place reactors.”

Xcellerex founder and chief technology officer Parrish Galliher noted, “The GreenVax project is an exciting outgrowth of the work we have been doing over the past several years with DARPA’s Accelerated Manufacture of Pharmaceuticals program. GreenVax has developed a very innovative process and we are pleased they selected the XDR system as an important part of their production train.”

Project GreenVax utilizes tobacco plants rather than the current egg-based vaccine technology, in hopes of shortening vaccine production to a fraction of the current time, allowing rapid response to newly emerging viruses not possible with current technology. The project is designed for final scale capacity of 100 million doses per month. The GreenVax Project will be headquartered on a secure, 21-acre site on the campus of the Texas A&M Health Science Center. The custom-designed 145,000-sq.-ft. biotherapeutic production facility will be constructed and managed by G-Con.